Pfizer Inc PFE
News
Pfizer Up Nearly 6%, on Pace for Largest Percent Increase Since December 2021 — Data Talk
Pfizer's first-quarter results top estimates, while drugmaker boosts full-year profit outlook
Pfizer Earnings Top Views; Boosts Full-Year Guidance
Pfizer Reports First-Quarter 2024 Results
Pfizer, Genmab Get Full FDA Approval for Cervical-Cancer Drug
Pfizer, Genmab get full FDA approval for cervical-cancer drug
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
Pfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual Meeting
Pfizer Gets FDA OK For Beqvez Gene Therapy for Hemophilia B
U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B
Pfizer Declares Second-Quarter 2024 Dividend
European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options
Obesity-drug power couple Novo Nordisk and Eli Lilly still have room to run, analysts say
Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25
Pfizer's Abrysvo Hits Key Goals in Adults at Increased RSV Risk
Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease
ALTIVIA Appoints Scott Barnum as Director of Manufacturing and Dean Hale as Corporate Engineering Manager
How a Biden-Trump rematch can keep healthcare ETFs afloat this election year